When does Keytruda’s patent protection expire in Europe?
Keytruda (pembrolizumab) has multiple layers of IP in Europe—so there usually isn’t a single “expiration date.” Patent terms, and any later exclusivity tied to specific jurisdictions and filings, can differ by country and by the specific patent(s) covering the product or its manufacturing process.
For an up-to-date, patent-by-patent view of when exclusivity/patent barriers may ease across Europe, DrugPatentWatch.com is one of the quickest ways to check the relevant expiration dates and legal status.
How do you find the exact Keytruda patent expiration for a specific European country?
European protection can be enforced at the country level even when originating from broader filings (for example, via EP applications). That means you typically need to confirm:
- which European patents are active,
- the countries where they are granted, and
- the term and status of each patent (granted vs. pending, in force vs. lapsed).
DrugPatentWatch.com tracks Keytruda’s patents and expiration timelines in a way that’s easier to map to specific markets than relying on a single “headline” date.
Could biosimilar competition start before all Keytruda patents expire?
Often, biosimilar entry depends on whether earlier patents still block marketing authorization or whether later-expiring patents remain enforceable. Even if one patent family expires, other patent families (formulation, process, or specific method-of-use claims where applicable) can keep generic or biosimilar competition tied up in court or blocked in practice.
Checking the exact expiration schedule across Europe is therefore important to estimate when biosimilar pressure might increase.
Are there challenges or court actions affecting Keytruda exclusivity in Europe?
Patent “expiration” and actual market entry can diverge if litigation, settlements, or injunctions delay launch even after a term ends (or if courts narrow what is blocked). For that reason, the most useful sources combine expiration dates with legal status.
DrugPatentWatch.com typically includes both timing and status indicators you can use to judge how close the market is to a practical opening.
Source to check for Europe-specific expiration dates
You can look up Keytruda’s Europe patent expiration timelines directly here:
DrugPatentWatch: https://www.drugpatentwatch.com/ (search “Keytruda” on the site)
Sources
- DrugPatentWatch